Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology has been informed that the FDA's Advisory Committee ODAC will review Neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer on May 24, 2017.

Puma Biotechnology, Inc.